(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included an advanced prostate cancer session and a presentation by Dr. Michael Morris discussing the VISION trial and integration of PSMA-targeted therapy for advanced prostate cancer. Dr. Morris notes that radioligand therapy has undergone an evolution in targeting from hydroxyapatite targeting to tumor targeting. Based on […]
(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included an advanced prostate cancer session and a presentation by Dr. Brian Chapin discussing the role of surgery and radiation in metastatic prostate cancer. Dr. Chapin emphasized that the rationale for definitive treatment of the primary tumor in metastatic prostate cancer has several bases. This includes […]
(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a prostate cancer session and a presentation by Dr. Gerald Andriole discussing the impact of 18F-fluciclovine PET/CT on plans for ADT in patients with biochemical recurrence of prostate cancer. Despite improvements in early detection and primary therapy, biochemical recurrence of prostate cancer after curative-intent primary […]
(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included the 2021 Richard D. Williams, MD Prostate Cancer Research Excellence Award Lecture with this year’s recipient being Dr. Gerald Andriole. As part of his receipt of this prestigious award, Dr. Andriole provided a discussion of considerations to improve screening in prostate cancer. Dr. Andriole started […]
(UroToday.com) Androgen deprivation therapy (ADT) has been a cornerstone in the treatment of advanced prostate cancer for decades. While initially indicated for patients with metastatic disease alone, its use has expanded. Thus, while ADT has proven survival benefits, there is an increasing need to understand the costs associated with its use in the management of biochemical […]
(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a kidney cancer session and a presentation by Dr. Jodi Maranchie discussing targeting HIF-2alpha in von-Hippel Lindau (VHL) patients. Dr. Maranchie starts by noting that the manifestations and penetrance of VHL lesions are highly variable based on anatomic location:
(UroToday.com) Neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) are standard of care for patients with muscle-invasive bladder cancer (MIBC). Despite level 1 evidence, and many guideline recommendations, supporting this approach, it is relatively underutilized in part due to the high patient burden from systemic toxicity and postoperative complications. Due to comorbidity or the toxicity of treatment, […]
(UroToday.com) It has been long recognized that, in the United States, Black men with prostate cancer have poorer outcomes than White men. This is, at least in part, driven by the fact that Black men are less likely to receive definitive therapy. Further, other health systems factors including sites of care and greater societal factors and […]
(UroToday.com) Neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) are standard of care for patients with muscle-invasive bladder cancer (MIBC). Despite level 1 evidence, and many guideline recommendations, supporting this approach, it is relatively underutilized in part due to the high patient burden from systemic toxicity and postoperative complications. Due to comorbidity or the toxicity of treatment, […]
(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL hosted the 2nd Annual Joseph A. Smith Jr. Mentorship lecture with this year’s recipient being Dr. Patrick C. Walsh, MD, University Distinguished Service Professor Emeritus at The James Buchanan Brady Urological Institute at Johns Hopkins Medicine.
